KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Operating Leases: 2019-2024

Historic Operating Leases for TherapeuticsMD (TXMD) over the last 6 years, with Dec 2024 value amounting to $5.5 million.

  • TherapeuticsMD's Operating Leases fell 6.34% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 6.34%. This contributed to the annual value of $5.5 million for FY2024, which is 30.77% down from last year.
  • According to the latest figures from FY2024, TherapeuticsMD's Operating Leases is $5.5 million, which was down 30.77% from $8.0 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's Operating Leases registered a high of $8.7 million during FY2020, and its lowest value of $5.5 million during FY2024.
  • Its 3-year average for Operating Leases is $7.0 million, with a median of $7.4 million in 2022.
  • In the last 5 years, TherapeuticsMD's Operating Leases rose by 8.63% in 2023 and then tumbled by 30.77% in 2024.
  • Over the past 5 years, TherapeuticsMD's Operating Leases (Yearly) stood at $8.7 million in 2020, then declined by 7.05% to $8.1 million in 2021, then declined by 8.61% to $7.4 million in 2022, then increased by 8.63% to $8.0 million in 2023, then slumped by 30.77% to $5.5 million in 2024.